CURIS INC
About CURIS INC
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $9.4M
- Net income
- -$7.6M
- Total assets
- $20.0M
- Market cap
- $18.4M
- Operating margin
- -60.5%
- Net margin
- -80.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $9.4M
- Operating expenses
- $15.2M
- Operating income
- -$5.7M
- Income tax
- $0
- Net income
- -$7.6M
- EPS (basic)
- $-0.58
- EPS (diluted)
- $-0.58
Balance sheet
- Total assets
- $20.0M
- Current assets
- $6.9M
- Total liabilities
- $14.5M
- Current liabilities
- $14.1M
- Shareholders’ equity
- $5.5M
Cash flow
- Operating cash flow
- -$27.2M
- Investing cash flow
- $2.5M
- Financing cash flow
- $9.8M
- Net cash flow
- -$14.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $18.4M
- EPS (diluted)
- $-0.58
- Shares outstanding
- 39.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 1, 2000
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $7.6M in FY2025.
- Revenue declined 11% from FY2021 to FY2025.
- Trading 83% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CURIS INC.
Write a review
News about CURIS INC
News & sentiment via Polygon.io
